China has unveiled an artificial intelligence platform for drug discovery that can screen a vast library of chemical compounds, cutting the initial drug screening phase from months or years down to tens of seconds. Developers said they expected the system to provide a novel method for identifying lead molecules to treat tumours, neurodegenerative conditions, rare diseases and emerging infectious diseases, as well as possibly speeding up drug research during public health crises. Called GalaxyVS,...
Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as cancer – decades before clinical symptoms appear. The partnership was announced as the global longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and...
China ranked third in a new global index measuring competitiveness in AI for biotechnology, healthcare and longevity, as the race to apply AI moves from chatbots and general-purpose models into regulated, data-heavy industries such as drug discovery, diagnostics and preventive medicine. The latest edition of the Global AI Competitiveness Index, released on Monday by Deep Knowledge Group, a consortium focused on deep-tech research, analytics and investment, ranked China behind only the US and UK...